Cecil-based generic drug giant Mylan Inc. said in a government filing today that it still plans to complete its deal to buy a chunk of Abbott Laboratories' overseas generics business in the first quarter next year and reincorporate in the Netherlands, but the two companies have slightly adjusted the terms of the transaction.

Under the new terms, shareholders of Mylan will own about 78 percent of the restructured company, down from about 79 percent as previously planned, according to a filing with the Securities and Exchange Commission.

The move follows new rules issued by the U.S. Treasury Department last month aimed at curbing so-called corporate inversions through which U.S. companies redomicile in countries with lower tax rates to cut their tax bills.

Patricia Sabatini: psabatini@post-gazette.com; 412-263-3066.